

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 17982

**Title:** Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations

**Reviewer's code:** 00181501

**Reviewer's country:** China

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2015-04-02 14:43

**Date reviewed:** 2015-05-08 11:28

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

This is a good review. However, if some content about the mechanism of hepatitis B virus reactivation is described, it will be much more attractive.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 17982

**Title:** Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations

**Reviewer's code:** 00013065

**Reviewer's country:** Germany

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2015-04-02 14:43

**Date reviewed:** 2015-05-21 16:30

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

In this interesting review article Drs. Mori and Fujiyama summarized the present knowledge of resolved HBV and HBV-reactivation in patients with rheumatic disease under various anti-rheumatic therapy options. The authors conducted a literature search and found a prevalence of 7.3% to 66% resolved HBV infection in rheumatic disease patients while depending on treatment strategy 1.7% to 8.6% of these patients revealed reactivation of HBV. Furthermore the authors discussed the current recommendations of antiviral treatment and screening for HBV of rheumatic disease patients under biological and/or non-biological DMARD treatment. Overall, the presented review article is comprehensive, well and appropriate referenced and yet concise in its content. The introduction introduces the following sections well. The review article is informative and very interesting to read. The tables are well constructed, concise, and easy to follow. The main and important aspect of the currently ongoing discussion of risk and prophylaxis of resolved HBV in rheumatic disease patients has been well addressed. Actually, there is no criticism with regard to the content and sufficiency of the manuscript. However, there are only very minor comments. 1. Minor typing errors should be



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

corrected (e.g., page 5, 2nd para, ...it has becomes... should read it has become) 2. page 7, 2nd, para;  
it should read ....in sera is very low (< (or less than) 10E3 copies/ml).

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 17982

**Title:** Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations

**Reviewer's code:** 03337012

**Reviewer's country:** Poland

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2015-04-02 14:43

**Date reviewed:** 2015-05-26 04:42

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

In this review the authors present the current knowledge regarding HBV reactivation after exposure to antirheumatic agents, mainly in patients with resolved infection. The authors intention was to clarify characteristics and risk of viral reactivation in this population. Prophylaxis against HBV reactivation was also described, as well as several aspects that need to be clarified for management of HBV reactivation in rheumatic disease patients. The manuscript is well written and prepared. The methodology of literature search and used definitions are well described. There are no major limitations that should be pointed out. The only minor issue is that the References, according to the Instructions for authors, should include the PMID and DOI numbers, which are lacking. However, it does not reduce the sufficiency of this review.